SP16

DRUG2 trials

Sponsors

Serpin Pharma, LLC

Conditions

Healthy ParticipantsInflammationMyocardial Infarction

Phase 1

SP16 SERPIN-like Peptide Administration in Healthy Individuals

CompletedNCT03651089

Serpin Pharma, LLCHealthy Participants

Start: 2018-07-16End: 2019-01-23Updated: 2021-07-28

SP16 Inflammatory Response Inhibition Trial

CompletedNCT04225533

Serpin Pharma, LLCInflammation, Myocardial Infarction

Start: 2020-02-24End: 2021-12-21Updated: 2023-01-30

Related Papers

Safety, Tolerability, and Effects of a Single Subcutaneous Administration of SP16 – a SERPIN-like, Small Peptide Agonist of the Low-Density Lipoprotein–like Receptor 1– on the Acute Inflammatory Response in Patients With ST-Segment Elevation Myocardial Infarction

Journal of Cardiovascular Pharmacology2022-07-124 citations